INGRESAR
CREAR CUENTA
Puntos de vista
El daño de la denominación puede ser mayor que el de la condición | 06 SEP 18

Dejar de denominar "cáncer" a condiciones de bajo riesgo

Quitar la etiqueta del cáncer en condiciones de bajo riesgo que es poco probable que causen daño si no se tratan puede ayudar a reducir el sobrediagnóstico y el sobretratamiento
9
Autor/a: Brooke Nickel, PhD candidate, Ray Moynihan, senior research fellow, Alexandra Barratt, professor of public health Renaming low risk conditions labelled as cancer
INDICE:  1. Página 1 | 2. Página 1
Página 1
  1.          Nickel B, Barratt A, Copp T, Moynihan R, McCaffery K. Words do matter: a systematic review on how different terminology for the same condition influences management preferences. BMJ Open2017;7:e014129. doi:10.1136/bmjopen-2016-014129. pmid:28698318
  2.         Esserman LJ, Thompson IM, Reid B, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol2014;15:e234-42. doi:10.1016/S1470-2045(13)70598-9. pmid:24807866
  3.         Allegra CJ, Aberle DR, Ganschow P, et al. NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). NIH Consens State Sci Statements2009;26:1-27.pmid:19784089
  4.         Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ2013;347:f4706. doi:10.1136/bmj.f4706. pmid:23982465
  5.         Østerø Í Jákupsstovu J, Brodersen J. Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer?BMJ2018;361:k1202. doi:10.1136/bmj.k1202. pmid:29724877
  6.         Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst2010;102:605-13. doi:10.1093/jnci/djq099. pmid:20413742
  7.         Furuya-Kanamori L, Bell KJ, Clark J, Glasziou P, Doi SA. Prevalence of Differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis. J Clin Oncol2016:JCO677419. doi:10.1200/JCO.2016.67.7419. pmid:27601555
  8.         Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? the increasing impact of overdiagnosis. N Engl J Med2016;375:614-7. doi:10.1056/NEJMp1604412. pmid:27532827
  9.         Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. Eur J Surg Oncol2018;44:307-15. doi:10.1016/j.ejso.2017.03.004. pmid:28343733
  10.         Jeon MJ, Kim WG, Kwon H, et al. Clinical outcomes after delayed thyroid surgery in patients with papillary thyroid microcarcinoma. Eur J Endocrinol2017;177:25-31. doi:10.1530/EJE-17-0160. pmid:28432268
  11.         Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol2015;1:888-96. doi:10.1001/jamaoncol.2015.2510. pmid:26291673
  12.         Hamdy FC, Donovan JL, Lane JA, et al., ProtecT Study Group. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med2016;375:1415-24. doi:10.1056/NEJMoa1606220. pmid:27626136
  13.         Francis A, Fallowfield L, Rea D. The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol (R Coll Radiol)2015;27:6-8. doi:10.1016/j.clon.2014.09.015. pmid:25445552
  14.         Elshof LE, Tryfonidis K, Slaets L, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ—the LORD study. Eur J Cancer2015;51:1497-510. doi:10.1016/j.ejca.2015.05.008. pmid:26025767
  15. ClinicalTrials.gov. Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for low risk DCIS. 2017 https://clinicaltrials.gov/ct2/show/NCT02926911.
  16.         Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ2005;331:481. doi:10.1136/bmj.38516.649537.E0. pmid:16081427
  17.         Mocellin S, Nitti D. Cutaneous melanoma in situ: translational evidence from a large population-based study. Oncologist2011;16:896-903. doi:10.1634/theoncologist.2010-0340. pmid:21632457
  18.         Patz EF Jr., Pinsky P, Gatsonis C, et al., NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med2014;174:269-74. doi:10.1001/jamainternmed.2013.12738. pmid:24322569
  19.         Schwartz LM, Woloshin S, Fowler FJ Jr., Welch HG. Enthusiasm for cancer screening in the United States. JAMA2004;291:71-8. doi:10.1001/jama.291.1.71. pmid:14709578
  20.         Waller J, Osborne K, Wardle J. Enthusiasm for cancer screening in Great Britain: a general population survey. Br J Cancer2015;112:562-6. doi:10.1038/bjc.2014.643. pmid:25535731
  21.         Kiviniemi MT, Hay JL. Awareness of the 2009 US Preventive Services Task Force recommended changes in mammography screening guidelines, accuracy of awareness, sources of knowledge about recommendations, and attitudes about updated screening guidelines in women ages 40-49 and 50+. BMC Public Health2012;12:899. doi:10.1186/1471-2458-12-899. pmid:23092125
  22.         Sirovich BE, Woloshin S, Schwartz LM. Screening for cervical cancer: will women accept less?Am J Med2005;118:151-8. doi:10.1016/j.amjmed.2004.08.021. pmid:15694900
  23.         Silver MI, Rositch AF, Burke AE, Chang K, Viscidi R, Gravitt PE. Patient concerns about human papillomavirus testing and 5-year intervals in routine cervical cancer screening. Obstet Gynecol2015;125:317-29. doi:10.1097/AOG.0000000000000638. pmid:25568994
  24.         Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J Natl Cancer Inst2009;101:1216-20. doi:10.1093/jnci/djp237. pmid:19671770
  25.         Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Cure me even if it kills me: preferences for invasive cancer treatment. Med Decis Making2005;25:614-9. doi:10.1177/0272989X05282639. pmid:16282212
  26.         Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM. Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med2013;173:1830-1. doi:10.1001/jamainternmed.2013.8405. pmid:23978843
  27.         Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P. Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol2015;67:233-8. doi:10.1016/j.eururo.2014.06.010. pmid:24993868
  28.         Orom H, Underwood W 3rd., Biddle C. Emotional distress increases the likelihood of undergoing surgery among men with localized prostate cancer. J Urol2017;197:350-5. doi:10.1016/j.juro.2016.08.007. pmid:27506694
  29.         Egger SJ, Calopedos RJ, O’Connell DL, et al. Long-term psychological and quality-of-life effects of active surveillance and watchful waiting after diagnosis of low-risk localised prostate cancer. Eur Urol2018;73:859-67. doi:10.1016/j.eururo.2017.08.013. pmid:28851582
  30.      &nbs
« Página anterior
 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

CONTENIDOS RELACIONADOS
Incidentalomas suprarrenales
Cribado del cáncer de próstata mediante el análisis del PSA
» Centro de Atención IntraMed
AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024